For instance, the CheckMate-069 trial combined Ipilimumab 3 mg/kg (anti CTLA-4) with Nivolumab 1 mg/kg and reported a proportion of 1:1000 cases of renal failure of grade 1-2 while Ipilimumab 3 mg/kg or Nivolumab 3 mg/kg alone reported 0:1000 and 2:1000 cases of renal failure respectively [7]. The gene discussed is CTLA4; the disease is kidney failure.